Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.9 USD | +0.71% |
|
+2.12% | -35.44% |
24/06 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
17/06 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.44% | 6.26B | |
+16.73% | 123B | |
+21.13% | 115B | |
+18.05% | 25.85B | |
-17.94% | 20.9B | |
-16.24% | 16.52B | |
-11.76% | 16.77B | |
-44.45% | 15.56B | |
+69.92% | 15.49B | |
+1.41% | 13.45B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Cytokinetics, Incorporated Announces Retirement of Peter S. Roddy, Senior Vice President and Chief Accounting Officer as of May 31, 2019